Go Pro
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel Free STEX Stock Alerts

Biosig Technologies (STEX) Financials

Biosig Technologies logo
$0.92 -0.04 (-4.64%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$0.92 0.00 (0.00%)
As of 07/9/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Biosig Technologies

Annual Income Statements for Biosig Technologies

This table shows Biosig Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.81 -12 -13 -36 -34 -52 -32 -27 -29 -11 -463
Consolidated Net Income / (Loss)		 -9.46 -12 -13 -35 -34 -59 -33 -27 -29 -10 -463
Net Income / (Loss) Continuing Operations		 -9.46 -12 -13 -17 -34 -59 -33 -27 -29 -10 -463
Total Pre-Tax Income 		-9.46 -12 -13 -17 -34 -59 -33 -27 -29 -10 -464
Total Operating Income		 -12 -11 -13 -17 -35 -59 -33 -27 -29 -13 -71
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.23 0.02 0.04 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.29 0.02 0.04 0.00
Operating Revenue		 - - - - - 0.00 0.44 0.29 0.02 0.04 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.06 0.00 0.00 0.00
Total Operating Expenses		 12 11 13 17 35 59 34 27 29 13 71
Selling, General & Admin Expense		 11 8.50 8.14 13 25 41 28 21 23 12 68
Research & Development Expense		 1.51 2.65 4.76 4.37 9.74 18 5.60 5.82 5.09 0.83 0.03
Depreciation Expense		 0.01 0.01 0.01 0.01 0.05 0.09 0.20 0.29 0.36 0.19 3.53
Impairment Charge		 - - - - - - - - 0.00 0.25 0.00
Total Other Income / (Expense), net		 2.58 -0.42 0.21 0.01 0.13 0.04 0.56 0.00 -0.18 2.52 -393
Interest Expense		 0.00 -0.00 -0.00 -0.01 -0.13 -0.05 -0.56 -0.00 -0.01 0.01 1.59
Other Income / (Expense), net		 2.58 -0.42 0.21 - 0.00 -0.00 - 0.00 -0.19 2.53 -391
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.25
Preferred Stock Dividends Declared		 0.35 0.11 0.12 0.88 0.03 0.01 0.01 0.22 0.01 0.18 0.01
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - 0.00 -0.42 -6.92 -0.94 -0.21 0.35 -0.01 0.02
Basic Earnings per Share		 ($0.70) ($0.60) ($1.25) ($1.25) ($1.65) ($1.87) ($0.95) ($6.33) ($3.95) ($0.75) ($9.65)
Weighted Average Basic Shares Outstanding		 14.10M 19.49M 10.22M 14.50M 20.69M 27.91M 33.51M 4.31M 7.35M 14.04M 47.97M
Diluted Earnings per Share		 ($0.70) ($0.60) ($1.25) ($1.25) ($1.65) ($1.87) ($0.95) ($6.33) ($3.95) ($0.75) ($9.65)
Weighted Average Diluted Shares Outstanding		 14.10M 19.49M 10.22M 14.50M 20.69M 27.91M 33.51M 4.31M 7.35M 14.04M 47.97M
Weighted Average Basic & Diluted Shares Outstanding		 14.10M 19.49M 10.22M 14.50M 20.69M 27.91M 33.51M 42.63M - - 97.72M

Quarterly Income Statements for Biosig Technologies

This table shows Biosig Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.57 -6.05 -3.54 -3.92 -1.94 -1.12 -2.81 -20 -16 -424 -47
Consolidated Net Income / (Loss)		 -4.05 -6.13 -3.42 -3.91 -1.91 -1.10 -2.80 -20 -16 -424 -47
Net Income / (Loss) Continuing Operations		 -4.05 -6.13 -3.42 -3.91 -1.91 -1.10 -2.80 -20 -16 -424 -47
Total Pre-Tax Income 		-4.05 -6.13 -3.42 -3.91 -1.91 -1.10 -2.80 -20 -16 -424 -47
Total Operating Income		 -4.05 -6.17 -3.44 -5.29 -2.95 -1.18 -2.98 -20 -6.11 -42 -36
Total Gross Profit		 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 - 0.00
Operating Revenue		 - - 0.01 0.01 0.00 0.01 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.05 6.18 3.45 5.31 2.95 1.20 2.98 20 6.11 42 36
Selling, General & Admin Expense		 2.82 4.91 2.88 4.91 2.76 1.07 2.96 20 4.62 40 34
Research & Development Expense		 1.15 1.18 0.24 0.34 0.16 0.10 0.01 0.02 0.01 - 0.00
Depreciation Expense		 0.09 0.09 0.08 0.05 0.03 0.03 0.02 0.55 1.49 1.47 1.49
Total Other Income / (Expense), net		 0.00 0.04 0.02 1.38 1.04 0.08 0.18 -0.00 -10 -383 -12
Interest Expense		 -0.00 -0.00 0.00 0.01 0.00 0.00 0.00 -0.01 0.01 1.60 15
Other Income / (Expense), net		 0.00 0.04 0.03 1.39 1.04 0.09 0.18 -0.02 -10 -381 3.74
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 -0.77 -0.49 -0.57
Preferred Stock Dividends Declared		 0.00 0.00 0.14 0.00 0.03 0.02 0.00 0.00 0.00 0.01 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.52 -0.08 -0.01 0.00 0.00 - 0.01 0.00 0.00 -0.00 -0.00
Basic Earnings per Share		 ($0.61) ($0.82) ($0.36) ($0.30) ($0.12) ($0.08) ($0.14) ($0.74) ($0.47) ($8.84) ($0.27)
Weighted Average Basic Shares Outstanding		 7.54M 7.35M 9.86M 12.92M 16.20M 14.04M 20.79M 27.71M 33.35M 47.97M 174.59M
Diluted Earnings per Share		 ($0.61) ($0.82) ($0.36) ($0.30) ($0.12) ($0.08) ($0.14) ($0.74) ($0.47) ($8.84) ($0.27)
Weighted Average Diluted Shares Outstanding		 7.54M 7.35M 9.86M 12.92M 16.20M 14.04M 20.79M 27.71M 33.35M 47.97M 174.59M
Weighted Average Basic & Diluted Shares Outstanding		 88.11M 0.00 12.48M 16.28M 17.23M 0.00 27.29M 31.42M 39.54M 97.72M 104.27M

Annual Cash Flow Statements for Biosig Technologies

This table details how cash moves in and out of Biosig Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.71 0.10 0.49 2.90 7.66 16 -17 -11 -0.17 -0.05 20
Net Cash From Operating Activities		 -4.52 -5.11 -7.47 -10 -15 -27 -26 -22 -17 -4.76 -10
Net Cash From Continuing Operating Activities		 -4.52 -5.11 -7.47 -10 -21 -27 -26 -22 -17 -4.76 -10
Net Income / (Loss) Continuing Operations		 -9.46 -12 -13 -17 -34 -59 -33 -27 -29 -10 -463
Consolidated Net Income / (Loss)		 -9.46 -12 -13 -17 -34 -59 -33 -27 -29 -10 -463
Depreciation Expense		 0.01 0.01 0.01 0.01 0.05 0.09 0.20 0.29 0.36 0.19 3.53
Amortization Expense		 0.59 0.00 0.00 - 0.35 0.46 0.44 - - 0.00 1.37
Non-Cash Adjustments To Reconcile Net Income		 4.85 6.42 5.09 6.56 19 30 9.33 4.80 9.93 5.02 449
Changes in Operating Assets and Liabilities, net		 -0.51 0.05 0.12 0.42 -0.39 2.37 -3.51 0.46 1.08 0.37 -1.19
Net Cash From Investing Activities		 -0.02 -0.02 -0.01 -0.31 -0.29 -0.09 -0.54 -0.17 -0.19 0.00 -24
Net Cash From Continuing Investing Activities		 -0.02 -0.02 -0.01 -0.31 -0.29 -0.09 -0.54 -0.17 -0.19 0.00 -24
Acquisitions		 - - 0.00 -0.27 -0.11 - - - - 0.00 0.37
Purchase of Investments		 - - - - - - - - - 0.00 -25
Net Cash From Financing Activities		 5.26 5.23 7.97 13 23 43 10 11 17 4.71 55
Net Cash From Continuing Financing Activities		 5.26 5.23 7.97 13 23 43 10 11 17 4.71 55
Repayment of Debt		 - - - - - - - - - 0.00 -8.05
Issuance of Debt		 - - - - - - - - 0.00 0.50 45
Issuance of Common Equity		 4.76 5.23 6.04 11 15 38 10 10 17 4.21 0.82
Other Financing Activities, net		 0.05 - 0.00 2.83 8.41 4.81 0.03 0.22 0.00 0.00 17
Effect of Exchange Rate Changes		 - - - - - - - - - 0.00 -0.02
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Biosig Technologies

This table details how cash moves in and out of Biosig Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.86 -0.20 0.23 1.69 -1.49 -0.47 3.59 -0.91 8.23 9.27 -13
Net Cash From Operating Activities		 -3.83 -2.94 -1.31 -1.48 -1.49 -0.47 -1.12 -1.28 -5.02 -3.02 -10
Net Cash From Continuing Operating Activities		 -3.83 -2.84 -1.31 -1.48 -1.49 -0.47 -1.12 -1.28 -5.02 -3.02 -10
Net Income / (Loss) Continuing Operations		 -4.05 -6.13 -3.42 -3.91 -1.91 -1.10 -2.80 -20 -16 -424 -47
Consolidated Net Income / (Loss)		 -4.05 -6.13 -3.42 -3.91 -1.91 -1.10 -2.80 -20 -16 -424 -47
Depreciation Expense		 0.09 0.09 0.08 0.05 0.03 0.03 0.02 0.56 1.49 1.47 1.49
Amortization Expense		 - - - - - - 0.00 - - - 12
Non-Cash Adjustments To Reconcile Net Income		 -0.36 2.21 1.38 2.97 5.30 -4.62 2.31 12 0.89 433 25
Changes in Operating Assets and Liabilities, net		 0.50 0.98 0.65 -0.59 -4.90 5.21 -0.65 6.15 8.19 -15 -1.72
Net Cash From Investing Activities		 -0.06 -0.00 0.00 - - - 0.00 0.37 -0.15 -24 -1.50
Net Cash From Continuing Investing Activities		 -0.06 -0.00 0.00 - - - 0.00 0.37 -0.15 -24 -1.50
Purchase of Property, Plant & Equipment		 -0.06 -0.00 - - - - 0.00 - - - -14
Purchase of Investments		 - - - - - - 0.00 - - -24 -24
Divestitures		 - - - - - - 0.00 - - - 0.03
Sale and/or Maturity of Investments		 - - - - - - 0.00 - - - 10
Other Investing Activities, net		 - - - - - - 0.00 - - - 26
Net Cash From Financing Activities		 3.03 2.75 1.54 3.17 - 0.00 4.70 - 13 37 -1.64
Net Cash From Continuing Financing Activities		 3.03 2.68 1.54 3.17 - 0.00 4.70 - 13 37 -1.64
Repayment of Debt		 - - - - - - 0.00 - - - -39
Issuance of Common Equity		 3.03 2.68 1.04 3.17 - 0.00 4.70 -3.88 14 -14 37
Other Financing Activities, net		 - - - - - - 0.00 - -0.18 13 -0.32
Other Net Changes in Cash		 - - - - - - - - - - -0.14
Cash Interest Paid		 - 0.00 0.00 - - - 0.00 - - - 0.40
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Biosig Technologies

This table presents Biosig Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.03 1.24 1.70 5.00 14 30 16 4.11 1.80 0.84 188
Total Current Assets		 0.98 1.19 1.66 4.63 13 29 14 1.13 0.53 0.39 72
Cash & Equivalents		 0.95 1.06 1.55 4.45 12 28 12 0.36 0.19 0.14 20
Short-Term Investments		 - - - - - - - 0.10 0.10 0.01 9.71
Accounts Receivable		 - - - - - - 0.00 0.01 0.02 0.11 0.01
Prepaid Expenses		 0.03 0.13 0.12 0.08 0.14 0.30 0.35 0.33 0.21 0.12 17
Current Deferred & Refundable Income Taxes		 - - - - - - - - - 0.00 0.05
Other Current Assets		 - - - 0.10 - - - 0.00 0.01 0.00 24
Plant, Property, & Equipment, net		 0.02 0.02 0.02 0.04 0.18 0.29 0.65 0.67 0.51 0.09 0.03
Total Noncurrent Assets		 0.03 0.03 0.02 0.32 1.21 0.76 0.97 2.32 0.76 0.37 116
Goodwill		 - - - - - - - - - 0.00 71
Intangible Assets		 - - 0.00 0.27 0.37 0.35 0.33 0.31 0.29 0.27 45
Other Noncurrent Operating Assets		 0.03 0.03 0.02 0.05 0.84 0.41 0.65 1.89 0.46 0.10 0.00
Total Liabilities & Shareholders' Equity		 1.03 1.24 1.70 5.00 14 30 16 4.11 1.80 0.84 188
Total Liabilities		 2.47 2.96 3.97 1.20 2.34 5.11 2.95 3.71 4.69 2.26 54
Total Current Liabilities		 2.47 2.96 3.97 1.20 2.03 5.11 2.58 3.26 4.58 2.26 43
Short-Term Debt		 - - - - - - - - - 0.00 38
Accounts Payable		 0.22 0.37 0.47 0.95 1.49 4.72 2.18 2.85 4.12 2.05 2.95
Dividends Payable		 0.34 0.36 0.45 0.24 0.13 0.07 0.08 0.09 0.10 0.11 0.12
Other Current Liabilities		 1.91 2.23 3.04 0.00 0.41 0.31 0.28 0.31 0.35 0.10 1.70
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.31 0.00 0.38 0.45 0.10 0.00 11
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 11
Commitments & Contingencies		 - - 0.00 0.00 - - 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 1.47 1.07 0.99 0.48 0.22 0.11 0.11 0.11 0.11 0.11 0.11
Total Equity & Noncontrolling Interests		 -2.91 -2.79 -3.25 3.32 12 25 12 0.29 -2.99 -1.53 133
Total Preferred & Common Equity		 -2.91 -2.79 -3.25 3.32 11 24 12 0.31 -3.02 -1.54 133
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -2.91 -2.79 -3.25 3.32 11 24 12 0.31 -3.02 -1.54 133
Common Stock		 29 41 53 74 116 181 201 216 242 254 850
Retained Earnings		 -32 -44 -57 -71 -105 -157 -189 -216 -245 -255 -718
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - - 0.00 0.81
Noncontrolling Interest		 - - - 0.00 0.51 0.80 0.22 -0.02 0.03 0.02 0.03

Quarterly Balance Sheets for Biosig Technologies

This table presents Biosig Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 3.15 1.59 3.11 1.42 4.42 110 131 173
Total Current Assets		 1.05 0.74 2.39 0.85 3.99 3.00 15 46
Cash & Equivalents		 0.39 0.42 2.10 0.62 3.73 2.82 11 6.86
Short-Term Investments		 0.10 0.09 0.07 0.04 0.00 0.00 0.00 24
Accounts Receivable		 0.01 0.01 0.05 0.08 0.11 0.01 0.01 0.00
Prepaid Expenses		 0.32 0.22 0.16 0.11 0.15 0.15 3.90 15
Current Deferred & Refundable Income Taxes		 - - - - - 0.02 0.04 0.06
Other Current Assets		 0.01 0.00 0.00 0.00 - - - 0.00
Plant, Property, & Equipment, net		 0.59 0.18 0.14 0.11 0.07 0.05 0.04 0.01
Total Noncurrent Assets		 1.51 0.67 0.58 0.46 0.36 107 115 127
Goodwill		 - - - - - 59 70 70
Intangible Assets		 0.29 0.28 0.28 0.27 0.27 48 45 42
Other Noncurrent Operating Assets		 1.17 0.38 0.30 0.18 0.10 0.06 0.04 15
Total Liabilities & Shareholders' Equity		 3.15 1.59 3.11 1.42 4.42 110 131 173
Total Liabilities		 4.10 5.79 2.99 1.70 1.68 113 137 14
Total Current Liabilities		 3.91 5.23 2.98 1.70 1.68 113 126 3.30
Short-Term Debt		 - - - - - - - 0.00
Accounts Payable		 3.47 4.82 2.60 1.45 1.51 7.57 9.77 3.18
Dividends Payable		 0.10 0.10 0.11 0.11 0.11 0.12 0.12 0.12
Other Current Liabilities		 0.34 0.31 0.27 0.15 0.06 106 116 0.00
Total Noncurrent Liabilities		 0.19 0.56 0.02 0.00 0.00 0.00 12 11
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - 12 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11
Total Equity & Noncontrolling Interests		 -1.06 -4.31 0.01 -0.39 2.63 -3.58 -6.93 159
Total Preferred & Common Equity		 -1.16 -4.32 -0.01 -0.41 2.61 -3.62 -6.96 159
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.16 -4.32 -0.01 -0.41 2.61 -3.62 -6.96 159
Common Stock		 238 244 252 254 261 273 288 925
Retained Earnings		 -239 -248 -252 -254 -258 -279 -294 -765
Accumulated Other Comprehensive Income / (Loss)		 - - - - - 1.54 -0.79 -1.10
Noncontrolling Interest		 0.11 0.01 0.02 0.02 0.03 0.03 0.03 0.26

Annual Metrics And Ratios for Biosig Technologies

This table displays calculated financial ratios and metrics derived from Biosig Technologies' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 28,313,748.00 16,663,978.00 22,172,170.00 30,248,713.00 35,310,627.00 48,020,467.00 88,107,565.00 17,234,929.00 39,540,603.00
DEI Adjusted Shares Outstanding		 0.00 0.00 1,132,550.00 1,666,398.00 2,217,217.00 3,024,871.00 3,531,063.00 4,802,047.00 8,810,756.00 17,234,929.00 39,540,603.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -11.32 -21.77 -15.37 -17.27 -9.04 -5.68 -3.30 -0.61 -11.70
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -35.15% -93.71% 122.22% -100.00%
EBITDA Growth		 -12.89% -30.60% -9.54% -36.03% -98.29% -71.43% 44.11% 17.70% -5.06% 64.22% -4,411.99%
EBIT Growth		 -11.80% -22.48% -9.57% -35.97% -100.46% -71.04% 43.55% 18.40% -5.26% 64.01% -4,377.36%
NOPAT Growth		 -53.07% 7.30% -15.60% -33.75% -100.46% -71.03% 43.55% 18.40% -4.57% 54.89% -452.74%
Net Income Growth		 -11.67% -22.47% -9.57% -178.73% 2.59% -71.56% 44.44% 17.03% -5.24% 63.96% -4,375.87%
EPS Growth		 23.08% 14.29% -108.33% 0.00% -32.00% -13.33% 49.20% 17.03% -5.24% 81.01% -1,186.67%
Operating Cash Flow Growth		 -126.52% -12.90% -46.26% -37.29% -50.97% -71.81% 0.76% 17.78% 20.24% 72.52% -119.36%
Free Cash Flow Firm Growth		 -23.73% -5.81% -8.43% -86.07% -63.08% -57.43% 29.32% 31.93% 11.74% 35.26% -1,715.11%
Invested Capital Growth		 -207.84% -17.57% -39.42% 87.87% 74.64% -2,719.73% 133.86% -51.21% -738.80% 52.35% 9,741.99%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.56% 85.71% -87.84% 0.00% -100.00%
EBITDA Q/Q Growth		 6.16% 5.32% -33.27% -3.79% -36.64% 7.52% 5.63% 6.99% 2.26% 32.89% -1,087.71%
EBIT Q/Q Growth		 5.80% 5.31% -33.27% -3.79% -38.01% 6.78% 5.47% 6.84% 2.19% 32.76% -1,038.52%
NOPAT Q/Q Growth		 4.13% 2.86% -34.57% -3.79% -38.01% 6.78% 5.47% 6.84% 2.83% 27.93% -131.99%
Net Income Q/Q Growth		 5.81% 5.31% -33.27% -82.00% 24.49% 14.19% -40.48% 6.84% 2.94% 32.72% -1,061.23%
EPS Q/Q Growth		 19.54% 9.09% -160.42% 20.38% -13.01% 16.89% 1.04% 6.84% 2.94% 21.05% -704.17%
Operating Cash Flow Q/Q Growth		 -16.20% -3.46% -15.30% -7.49% -6.41% -9.03% 1.39% 6.93% 6.34% 34.15% -32.28%
Free Cash Flow Firm Q/Q Growth		 0.00% -1.77% -36.26% 1.60% -36.31% 6.47% 6.15% 8.99% 8.03% 17.15% -4,289.58%
Invested Capital Q/Q Growth		 3.94% 15.54% 7.53% -9,064.69% -123.11% -7.79% -39.50% -69.12% -167.74% -76.96% 890.61%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.88% 80.07% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,431.29% -9,430.77% -157,433.33% -25,350.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,576.19% -9,533.22% -158,400.00% -32,155.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,576.19% -9,533.22% -159,438.89% -25,820.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,450.34% -9,532.17% -159,388.89% -25,847.50% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 205.13% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.73%
Interest Burden Percent		 100.01% 100.00% 100.00% 99.94% 99.62% 99.92% 98.34% 99.99% 99.97% 100.11% 100.34%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,596.67% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,454.37% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,176.02% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 818.57% 734.10% 637.65% -4,612.46% -439.81% -318.36% -173.65% -420.65% 2,304.42% 479.88% -701.65%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,762.52% -2,527.82% 0.00% 0.00% -136.22%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -145.57% -277.80% -971.53% -782.42% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -143.15% -277.77% -971.23% -783.26% 0.00%
Return on Common Equity (ROCE)		 2,299.42% 1,324.99% 966.72% -223.72% -406.00% -304.33% -168.00% -407.40% 2,503.39% 508.06% -700.27%
Return on Equity Simple (ROE_SIMPLE)		 325.07% 415.73% 390.66% -1,064.52% -309.27% -242.68% -268.41% 0.00% 950.63% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.43 -7.81 -9.03 -12 -24 -41 -23 -19 -20 -9.00 -50
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,303.33% -6,673.25% -110,880.00% -22,508.50% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -505.64% -576.37% -407.79% -878.24% -126.62% -88.17% -47.61% -142.30% -16,320.75% -1,127.09% 10,228.96%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 667.06% 589.61% -29.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 45.12% 19.93% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,315.87% 7,475.52% 128,205.56% 29,072.50% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,270.29% 2,035.31% 28,288.89% 2,080.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7,631.07% 9,613.29% 158,500.00% 32,255.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.46 -12 -13 -17 -35 -59 -33 -27 -29 -10 -462
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.86 -12 -13 -17 -34 -59 -33 -27 -28 -10 -458
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 18.63 10.99 4.47 6.11 57.80 0.00 0.00 1.09
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 20.28 11.36 4.53 6.27 3,015.07 0.00 0.00 8.27
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 169.46 63.25 1,940.06 523.06 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 64.17 37.69 0.00 0.00 1.09
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 143.76 63.53 1,931.06 522.23 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.14 0.00 0.00 0.29
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.14 0.00 0.00 0.00
Financial Leverage		 0.18 0.41 0.45 -3.46 -1.03 -1.08 -1.05 -0.89 0.04 0.06 0.06
Leverage Ratio		 -0.60 -0.72 -0.74 4.36 1.23 1.20 1.21 1.51 -2.37 -0.61 1.43
Compound Leverage Factor		 -0.60 -0.72 -0.74 4.36 1.22 1.20 1.19 1.51 -2.37 -0.61 1.43
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 53.24% 0.00% 0.00% 22.19%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.19%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 53.24% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -102.18% -62.31% -43.49% 12.50% 6.15% 3.59% 2.58% 9.89% -4.54% -8.58% 0.08%
Common Equity to Total Capital		 202.18% 162.31% 143.49% 87.50% 93.85% 96.41% 97.42% 36.87% 104.54% 108.58% 77.73%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00 0.00 -0.08
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00 0.00 -0.76
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.64 13.96 0.08 -8.07 -93.09 -241.68 -462.12 -11.70
Noncontrolling Interest Sharing Ratio		 -180.91% -80.49% -51.61% 95.15% 7.69% 4.41% 3.25% 3.15% -8.63% -5.87% 0.20%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.40 0.40 0.42 3.87 6.32 5.74 5.39 0.35 0.12 0.17 1.68
Quick Ratio		 0.39 0.36 0.39 3.72 5.97 5.53 4.53 0.14 0.07 0.12 0.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.05 -7.45 -8.08 -15 -25 -39 -27 -19 -16 -11 -193
Operating Cash Flow to CapEx		 -28,517.63% -31,420.81% -79,165.47% -26,375.09% -8,898.28% -30,575.86% -4,870.66% -12,919.64% -9,308.06% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -5,427.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -965.04 -121.03
Operating Cash Flow to Interest Expense		 -3,485.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -432.55 -6.56
Operating Cash Flow Less CapEx to Interest Expense		 -3,497.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -432.55 -6.56
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.01 0.03 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.09 0.60 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.05 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.94 0.43 0.03 0.13 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.02 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 334.58 606.81 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 2,429.36 7,098.29 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 6,328.81 16,108.03 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -3,899.45 -9,009.74 334.58 606.81 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.05 -2.41 -3.36 -0.41 -0.10 -2.92 0.99 0.48 -3.08 -1.47 141
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 -0.46 0.39 -0.01 -0.02 0.00
Increase / (Decrease) in Invested Capital		 -1.39 -0.36 -0.95 2.96 0.30 -2.81 3.91 -0.51 -3.56 1.61 143
Enterprise Value (EV)		 0.00 0.00 0.00 58 111 81 63 18 35 21 153
Market Capitalization		 0.00 0.00 0.00 62 123 109 75 18 35 21 145
Book Value per Share		 ($0.21) ($0.14) ($0.11) $0.20 $0.50 $0.81 $0.35 $0.01 ($0.03) ($0.09) $3.37
Tangible Book Value per Share		 ($0.21) ($0.14) ($0.11) $0.18 $0.49 $0.79 $0.34 $0.00 ($0.04) ($0.11) $0.44
Total Capital		 -1.44 -1.72 -2.26 3.80 12 25 13 0.85 -2.89 -1.42 171
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.00 0.00 38
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.00 0.00 0.00
Net Debt		 -0.95 -1.06 -1.55 -4.45 -12 -28 -12 -0.01 -0.29 -0.16 8.00
Capital Expenditures (CapEx)		 0.02 0.02 0.01 0.04 0.17 0.09 0.54 0.17 0.19 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.44 -2.82 -3.85 -1.02 -1.31 -4.04 -0.34 -2.59 -4.35 -2.03 37
Debt-free Net Working Capital (DFNWC)		 -1.49 -1.77 -2.30 3.43 11 24 11 -2.13 -4.05 -1.88 67
Net Working Capital (NWC)		 -1.49 -1.77 -2.30 3.43 11 24 11 -2.13 -4.05 -1.88 29
Net Nonoperating Expense (NNE)		 1.03 3.77 3.66 23 10 18 9.47 8.18 8.73 1.34 413
Net Nonoperating Obligations (NNO)		 -0.61 -0.70 -1.10 -4.21 -12 -28 -12 0.09 -0.19 -0.05 8.12
Total Depreciation and Amortization (D&A)		 0.60 0.01 0.01 0.01 0.40 0.55 0.64 0.29 0.36 0.19 4.91
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -77.32% -905.94% -24,150.00% -5,077.50% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,566.44% -745.80% -22,522.22% -4,690.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,566.44% -745.80% -22,522.22% -4,690.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.00) ($6.00) ($5.00) ($12.50) ($16.50) ($18.70) ($9.50) ($6.40) ($3.95) ($0.75) ($9.65)
Adjusted Weighted Average Basic Shares Outstanding		 1.73M 2.41M 3.00M 1.97M 2.60M 3.18M 3.84M 6.69M 7.35M 14.04M 47.97M
Adjusted Diluted Earnings per Share		 ($7.00) ($6.00) ($5.00) ($12.50) ($16.50) ($18.70) ($9.50) ($6.40) ($3.95) ($0.75) ($9.65)
Adjusted Weighted Average Diluted Shares Outstanding		 1.73M 2.41M 3.00M 1.97M 2.60M 3.18M 3.84M 6.69M 7.35M 14.04M 47.97M
Adjusted Basic & Diluted Earnings per Share		 ($7.00) ($6.00) ($5.00) ($12.50) ($16.50) ($18.70) ($9.50) ($6.40) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.41M 1.95M 2.56M 1.45M 2.07M 2.79M 3.35M 4.26M 0.00 0.00 97.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.43 -7.81 -9.03 -12 -24 -41 -23 -19 -20 -8.83 -50
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,303.33% -6,673.25% -110,880.00% -22,065.75% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,450.34% -9,532.17% -159,388.89% -25,847.50% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7,288.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -938.91 -290.47
NOPAT to Interest Expense		 -6,495.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -818.49 -31.26
EBIT Less CapEx to Interest Expense		 -7,300.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -938.91 -290.47
NOPAT Less CapEx to Interest Expense		 -6,507.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -818.49 -31.26
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Biosig Technologies

This table displays calculated financial ratios and metrics derived from Biosig Technologies' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 74,927,499.00 88,107,565.00 88,107,565.00 12,476,413.00 16,278,346.00 17,234,929.00 17,234,929.00 27,294,604.00 31,418,795.00 39,540,603.00 97,721,696.00
DEI Adjusted Shares Outstanding		 7,492,750.00 8,810,756.00 8,810,756.00 12,476,413.00 16,278,346.00 17,234,929.00 17,234,929.00 27,294,604.00 31,418,795.00 39,540,603.00 97,721,696.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.61 -0.69 -0.40 -0.31 -0.12 -0.06 -0.16 -0.75 -0.50 -10.72 -0.48
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% -90.91% 180.00% 0.00% 0.00% 0.00% -100.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 38.16% 12.71% 54.34% 65.07% 52.44% 82.34% 16.65% -414.00% -688.69% -39,434.05% -567.00%
EBIT Growth		 37.54% 12.42% 53.80% 64.92% 52.75% 82.12% 17.94% -421.79% -753.66% -38,485.95% -1,043.11%
NOPAT Growth		 37.54% 11.87% 53.47% 51.49% 27.18% 80.82% 13.18% -284.83% -107.22% -3,419.19% -1,097.92%
Net Income Growth		 37.55% 12.41% 53.74% 64.86% 52.74% 82.07% 18.01% -420.79% -714.21% -38,481.26% -1,567.64%
EPS Growth		 37.55% 12.41% 69.75% 81.01% 80.33% 90.24% 61.11% -146.67% -291.67% -10,950.00% -92.86%
Operating Cash Flow Growth		 22.62% 28.49% 76.74% 69.74% 61.10% 83.89% 15.14% 13.71% -237.34% -537.34% -812.91%
Free Cash Flow Firm Growth		 97.21% 82.79% 146.46% 43.11% -1,813.39% -222.81% -341.64% -278.47% 635.75% -6,951.24% -2,809.34%
Invested Capital Growth		 -173.67% -738.80% -919.56% -118.63% 27.91% 52.35% 78.67% -217.45% -2,058.14% 9,741.99% 14,808.22%
Revenue Q/Q Growth		 0.00% 0.00% 7.69% -7.14% -100.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 64.14% -52.46% 44.76% -15.69% 51.18% 43.39% -160.69% -613.39% 25.09% -2,737.74% 95.60%
EBIT Q/Q Growth		 63.61% -51.30% 44.33% -14.48% 51.00% 42.74% -155.47% -627.89% 19.83% -2,488.30% 92.43%
NOPAT Q/Q Growth		 62.86% -52.23% 44.27% -53.97% 44.26% 59.90% -152.24% -582.47% 69.98% -581.04% 14.14%
Net Income Q/Q Growth		 63.61% -51.31% 44.27% -14.52% 51.06% 42.58% -154.78% -627.43% 23.49% -2,620.79% 88.99%
EPS Q/Q Growth		 63.61% -51.31% 56.10% 16.67% 60.00% 33.33% -75.00% -428.57% 36.49% -1,780.85% 96.95%
Operating Cash Flow Q/Q Growth		 21.80% 23.15% 55.34% -12.71% -0.54% 68.17% -135.23% -14.62% -293.04% 39.86% -236.94%
Free Cash Flow Firm Q/Q Growth		 97.32% -506.17% 391.19% -220.28% 9.87% -2.27% -117.97% -88.38% 227.58% -1,446.00% 10.06%
Invested Capital Q/Q Growth		 -29.07% -167.74% -33.36% 52.56% 57.44% -76.96% 40.29% -605.94% -189.31% 890.61% -8.91%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -46,430.77% -23,814.29% -29,669.23% 0.00% -8,200.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -47,438.46% -24,550.00% -40,707.69% 0.00% -9,100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -47,146.15% -24,371.43% -30,046.15% 0.00% -8,430.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -47,138.46% -24,392.86% -30,084.62% 0.00% -8,453.85% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 95.32% 99.88% 98.80%
Interest Burden Percent		 99.98% 99.98% 100.09% 100.13% 100.00% 100.27% 100.00% 99.94% 100.06% 100.38% 147.65%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 2,304.42% 2,259.87% -6,342.03% 2,492.78% 479.88% 1,328.42% 1,557.00% 1,121.93% -701.65% -625.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -136.22% -157.10%
Operating Return on Assets (OROA)		 0.00% -287.28% -193.94% -335.85% 0.00% -255.48% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -287.24% -194.11% -336.28% 0.00% -256.18% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 2,503.39% 2,422.03% -2,711.45% 3,163.99% 508.06% 1,557.08% 1,677.38% 1,162.99% -700.27% -623.26%
Return on Equity Simple (ROE_SIMPLE)		 2,548.10% 0.00% 572.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.84 -4.32 -2.41 -3.70 -2.07 -0.83 -2.09 -14 -4.28 -29 -25
NOPAT Margin		 0.00% -33,206.92% -17,185.00% -28,495.38% 0.00% -6,370.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -420.17% -3,385.23% -142.43% -12.19% 40.48% -228.61% -40.43% -256.34% -194.64% 9,779.95% -127.04%
Return On Investment Capital (ROIC_SIMPLE)		 - 144.28% 63.18% -33,676.36% 532.22% 54.23% -79.30% 397.75% 61.78% -17.02% -15.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 37,769.23% 20,585.71% 37,800.00% 0.00% 8,230.77% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 9,046.15% 1,700.00% 2,630.77% 0.00% 738.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 47,530.77% 24,650.00% 40,807.69% 0.00% 9,200.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.05 -6.13 -3.41 -3.91 -1.91 -1.10 -2.80 -20 -16 -423 -32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.96 -6.04 -3.33 -3.86 -1.88 -1.07 -2.78 -20 -15 -421 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 4.80 0.00 0.00 1.09 1.24
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 5.34 0.00 0.00 8.27 4.21
Price to Revenue (P/Rev)		 249.19 1,940.06 241.30 83.96 137.71 523.06 480.68 15,217.42 14,777.50 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.09 1.30
Enterprise Value to Revenue (EV/Rev)		 248.59 1,931.06 245.44 32.78 124.41 522.23 342.49 15,011.11 13,927.58 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.20 0.00 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.29 0.00
Long-Term Debt to Equity		 -0.20 0.00 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.58 0.04 0.65 -6.14 0.61 0.06 2.40 1.42 1.64 0.06 -0.21
Leverage Ratio		 8.26 -2.37 -3.10 12.97 -3.71 -0.61 -4.10 -33.55 -18.57 1.43 1.10
Compound Leverage Factor		 8.26 -2.37 -3.10 12.98 -3.71 -0.61 -4.10 -33.53 -18.58 1.43 1.62
Debt to Total Capital		 -25.50% 0.00% -13.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.19% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.19% 0.00%
Long-Term Debt to Total Capital		 -25.50% 0.00% -13.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -27.74% -4.54% -3.19% 105.17% -43.11% -8.58% 4.89% -3.97% -2.02% 0.08% 0.23%
Common Equity to Total Capital		 153.24% 104.54% 116.69% -5.17% 143.11% 108.58% 95.11% 103.97% 102.02% 77.73% 99.77%
Debt to EBITDA		 -0.01 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 -0.08 0.00
Net Debt to EBITDA		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00
Long-Term Debt to EBITDA		 -0.01 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.01 0.00 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 -0.76 0.00
Net Debt to NOPAT		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16 0.00
Long-Term Debt to NOPAT		 -0.01 0.00 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -105.96 -200.25 -228.66 -117.39 -254.22 -425.94 -78.80 -4.32 -3.75 -11.01 1.98
Noncontrolling Interest Sharing Ratio		 0.00% -8.63% -7.18% 57.25% -26.93% -5.87% -17.21% -7.73% -3.66% 0.20% 0.31%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.27 0.12 0.14 0.80 0.50 0.17 2.37 0.03 0.12 1.68 13.90
Quick Ratio		 0.13 0.07 0.10 0.75 0.43 0.12 2.28 0.03 0.09 0.70 9.27
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.12 -0.76 2.20 -2.65 -2.39 -2.44 -5.32 -10 13 -172 -155
Operating Cash Flow to CapEx		 -6,380.00% -73,550.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -71.56%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 733.70 -529.48 0.00 -813.37 0.00 0.00 1,278.29 -107.87 -10.15
Operating Cash Flow to Interest Expense		 0.00 0.00 -438.00 -296.20 0.00 -158.00 0.00 0.00 -502.30 -1.89 -0.67
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -438.00 -296.20 0.00 -158.00 0.00 0.00 -502.30 -1.89 -1.60
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.04 0.01 0.01 0.01 0.02 0.03 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 15.58 1.09 1.74 1.00 0.84 0.60 0.42 0.40 0.28 0.00 0.00
Inventory Turnover		 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.23 0.03 0.07 0.11 0.11 0.13 0.21 0.14 0.17 0.00 0.00
Accounts Payable Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 23.43 334.58 209.54 365.00 433.44 606.81 863.37 912.50 1,291.54 0.00 0.00
Days Inventory Outstanding (DIO)		 12,910.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 37,595.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -24,661.39 334.58 209.54 365.00 433.44 606.81 863.37 912.50 1,291.54 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.15 -3.08 -4.11 -1.95 -0.83 -1.47 -0.88 -6.18 -18 141 129
Invested Capital Turnover		 0.72 -0.01 -0.02 -0.03 -0.04 -0.02 -0.01 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.71 -3.56 -4.61 -1.06 0.32 1.61 3.23 -4.24 -17 143 130
Enterprise Value (EV)		 37 35 6.63 1.31 4.98 21 8.90 195 181 153 167
Market Capitalization		 37 35 6.51 3.36 5.51 21 12 198 192 145 197
Book Value per Share		 ($0.02) ($0.03) ($0.05) $0.00 ($0.02) ($0.09) $0.15 ($0.13) ($0.22) $3.37 $4.02
Tangible Book Value per Share		 ($0.02) ($0.04) ($0.05) ($0.02) ($0.04) ($0.11) $0.14 ($4.04) ($3.89) $0.44 $1.18
Total Capital		 -0.76 -2.89 -3.70 0.12 -0.28 -1.42 2.74 -3.48 -6.82 171 159
Total Debt		 0.19 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 38 0.00
Total Long-Term Debt		 0.19 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.30 -0.29 -0.01 -2.17 -0.65 -0.16 -3.73 -2.82 -11 8.00 -31
Capital Expenditures (CapEx)		 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.35 -4.35 -5.00 -2.76 -1.51 -2.03 -1.42 -113 -122 37 12
Debt-free Net Working Capital (DFNWC)		 -2.86 -4.05 -4.49 -0.59 -0.85 -1.88 2.31 -110 -111 67 43
Net Working Capital (NWC)		 -2.86 -4.05 -4.49 -0.59 -0.85 -1.88 2.31 -110 -111 29 43
Net Nonoperating Expense (NNE)		 1.21 1.81 1.01 0.21 -0.15 0.27 0.71 6.11 11 395 22
Net Nonoperating Obligations (NNO)		 -0.20 -0.19 0.10 -2.06 -0.55 -0.05 -3.62 -2.71 -11 8.12 -31
Total Depreciation and Amortization (D&A)		 0.09 0.09 0.08 0.05 0.03 0.03 0.02 0.56 1.49 1.47 13
Debt-free, Cash-free Net Working Capital to Revenue		 -2,264.19% -24,150.00% -18,511.11% -6,897.50% -3,767.50% -5,077.50% -5,461.54% -869,376.92% -935,792.31% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 -1,932.43% -22,522.22% -16,637.04% -1,475.00% -2,132.50% -4,690.00% 8,873.08% -847,684.62% -850,830.77% 0.00% 0.00%
Net Working Capital to Revenue		 -1,932.43% -22,522.22% -16,637.04% -1,475.00% -2,132.50% -4,690.00% 8,873.08% -847,684.62% -850,830.77% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.60) ($8.20) ($0.36) ($0.30) ($0.12) ($0.08) ($0.14) ($0.74) ($0.47) ($8.84) ($0.27)
Adjusted Weighted Average Basic Shares Outstanding		 7.54M 735.18K 9.86M 12.92M 16.20M 14.04M 20.79M 27.71M 33.35M 47.97M 174.59M
Adjusted Diluted Earnings per Share		 ($0.60) ($8.20) ($0.36) ($0.30) ($0.12) ($0.08) ($0.14) ($0.74) ($0.47) ($8.84) ($0.27)
Adjusted Weighted Average Diluted Shares Outstanding		 7.54M 735.18K 9.86M 12.92M 16.20M 14.04M 20.79M 27.71M 33.35M 47.97M 174.59M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($8.20) $0.00 $0.00 $0.00 ($0.08) $0.00 $0.00 $0.00 ($8.84) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.81M 0.00 12.48M 16.28M 17.23M 0.00 27.29M 31.42M 39.54M 97.72M 104.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.84 -4.32 -2.23 -3.70 -2.07 -0.83 -2.09 -14 -4.28 -29 -25
Normalized NOPAT Margin		 0.00% -33,206.92% -15,920.00% -28,495.38% 0.00% -6,370.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -47,138.46% -24,392.86% -30,084.62% 0.00% -8,453.85% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -1,137.33 -781.20 0.00 -365.33 0.00 0.00 -1,633.90 -265.14 -2.10
NOPAT to Interest Expense		 0.00 0.00 -801.97 -740.88 0.00 -276.03 0.00 0.00 -427.91 -18.27 -1.64
EBIT Less CapEx to Interest Expense		 0.00 0.00 -1,137.33 -781.20 0.00 -365.33 0.00 0.00 -1,633.90 -265.14 -3.03
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -801.97 -740.88 0.00 -276.03 0.00 0.00 -427.91 -18.27 -2.57
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Biosig Technologies Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Biosig Technologies' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Biosig Technologies' net income appears to be on an upward trend, with a most recent value of -$462.76 million in 2025, rising from -$9.46 million in 2015. The previous period was -$10.34 million in 2024. Find out what analysts predict for Biosig Technologies in the coming months.

Biosig Technologies' total operating income in 2025 was -$71.09 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $71.09 million

Over the last 10 years, Biosig Technologies' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Biosig Technologies' total liabilities were at $54.22 million at the end of 2025, a 2,294.7% increase from 2024, and a 2,094.8% increase since 2015.

In the past 10 years, Biosig Technologies' cash and equivalents has ranged from $142 thousand in 2024 to $28.27 million in 2020, and is currently $20.32 million as of their latest financial filing in 2025.

Over the last 10 years, Biosig Technologies' book value per share changed from -0.21 in 2015 to 3.37 in 2025, a change of -1,732.0%.


Related Companies

Financial statements for NASDAQ:STEX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The tiny chipmaker set to supply Musk 5 billion chips
SpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsof...
Brownstone Research | Sponsoredtc pixel
The market’s crashing? … There’s an app for that
During the Great Financial Crisis, one firm accurately predicted 464 of 465 bank failures before they happened...
Weiss Ratings | Sponsoredtc pixel